Background
==========

Metastatic colorectal cancer (mCRC) is the second most common cause of cancer death in the Western world accounting for 40-50% of newly diagnosed patients \[[@B1]\]. Despite therapeutic advances, the prognosis for patients with mCRC remains poor. However, the addition of drugs such as irinotecan and oxaliplatin to 5-fluorouracil (5-FU) has almost doubled the median survival from 12 months to 21 months \[[@B2]\]. Monoclonal antibodies (mAbs) binding to the vascular endothelial growth factor (VEGF) (bevacizumab) or the epidermal growth factor receptor (EGFR) (cetuximab and panitumumab) have shown efficacy in the treatment of mCRC increasing the life expectancy of patients by more than 2 years \[[@B3]\]. While bevacizumab is administered in combination with chemotherapy as a first-line treatment, anti-EGFR mAbs find place in later-line treatments.

Cetuximab is an IgG1a chimeric mAb while panitumumab is a fully human IgG2 mAb; they bind to EGFR and block the binding of its natural ligands, preventing ligand dependent homodimerization and activation of intracellular cascades that control cellular proliferation, adhesion, angiogenesis, and apoptosis. Anti-EGFR mAbs have proven to be effective in combination with chemotherapy or as single agents for treatment of mCRC \[[@B3]\]. Recent evidences showed that mCRC responds differently to EGFR-targeted agents on genetic basis that involve also the EGFR downstream effectors (i.e. kras, braf, PIK3CA and PTEN) \[[@B4]\]. Although largely unexplored, monoclonal antibodies also induce antibody-dependent cell-mediated cytotoxicity (ADCC) \[[@B5]-[@B8]\]. ADCC is induced through the interaction of the Fc region of the mAb with the Fc gamma receptor (FcγR) expressed by effector cells (i.e. natural killer-NK-lymphocytes, monocytes/macrophages). Polymorphisms have been demonstrated on genes encoding for the activating receptors FcγRIIa (CD32, mainly expressed on macrophages) and FcγRIIIa (CD16, expressed on NK cells and macrophages) \[[@B9]\], affecting their affinity to human IgG: a histidine (H)/arginine (R) polymorphism at position 131 for FcγRIIa and a valine (V)/phenylalanine (F) polymorphism at position 158 for FcγRIIIa. Based on the different affinities, patients harboring FcγRIIa-131H/H and FcγRIIIa-4 158V/V genotypes would be expected to mediate a more efficient ADCC antitumor response. Clinical studies utilizing rituximab in the treatment of B-cell non-Hodgkin's lymphoma have shown that FcγRIIa-131H/H and FcγRIIIa-158V/V genotypes were associated with better clinical outcome \[[@B10],[@B11]\]. Patients with 158V/V and/or 131 H/H had a significantly higher response rate than patients without either genotype (59% vs 18%). The progression-free survival (PFS) estimate of patients with 158V/V and/or 131H/H allele was also significantly longer, with median PFS of 445 and 140 days for the two groups, respectively \[[@B11]\]. Nevertheless it was shown that when CT is added to Rituximab the predictive value of FCGR polymorphisms was lost probably due to the high efficacy of CT \[[@B12]\]. In trastuzumab-treated metastatic breast cancer, ADCC analysis showed that the combination of 158 V/V and/or 131 H/H had a significantly higher trastuzumab-mediated cytotoxicity than other genotypes in addition to higher response rate and a longer PFS \[[@B13]\]. Contrasting results have been reported on the role of FcγR polymorphisms in mCRC \[[@B14],[@B15]\]. Recently, it was described that FcγRIIa-131H/H and FcγRIIIa-158F/F polymorphisms associated with better PFS in a series of EGFR-expressing mCRC patients treated with single-agent cetuximab \[[@B14]\]. Conversely, Bibeau et al. demonstrated a favourable effect on PFS only for the FcγRIIIA-158V/V genotype unrelated to the kras status \[[@B15]\]. The goal of our study was to explore the association between FcγRIIa and FcγRIIIa polymorphisms and the outcome of mCRC patients treated with anti-EGFR-based therapies (cetuximab and panitumumab).

Methods
=======

Patient management and follow-up
--------------------------------

Seventy-four stage IV CRC patients were studied at the Division of Abdominal Medical Oncology of the National Cancer Institute (Naples, Italy) from May 2007 to May 2009. Patients were eligible after specific discussion on the study. Informed consent from each patient was sought. The protocol was conducted according to a protocol approved by the institutional review board/independent ethics committee. Patients were routinely characterized for kras mutational status \[[@B16]\]. All patients underwent to sequential standard treatments based on chemotherapy and/or biologic therapies (bevacizumab, cetuximab, panitumumab). First and second-line chemotherapy (CT) included the association of fluoropyrimidines (capecitabine or 5-fluoruracile) with oxaliplatin or irinotecan. The chemotherapy regimen was based on patient\'s performance status, extent of disease, comorbidities, previous treatments and individual preferences. Some selected patients underwent pulmonary and/or liver metastasectomies as established in a multidisciplinary team discussion. Bone metastases were treated with palliative radiotherapy. Patients features are shown in Table  [1](#T1){ref-type="table"}. Cetuximab or panitumumab were administered only in patients with kras wilde-type (wt) tumors. All patients underwent first-line chemotherapy, 54 patients (72.9%) received a second-line chemotherapy and 22 (29.7%) a third-line chemotherapy. Eight patients received palliative radiotherapy. Eleven patients with advanced disease underwent to palliative resection of primary colonic tumor. Metastasectomies before or after chemotherapy were performed in 26 patients. Total body computed tomography scan and CEA monitoring were done every three months. The response to therapy was evaluated by RECIST criteria. Patients with target metastatic lesions restaged at the Radiology Unit were considered for response evaluation.

###### 

Detailed characteristics of patients and tumors

  **Patient Initials**    **Gender**   **Age (years)**   **Mucinous component\>50%**   **Primary tumor**   **Grading**   **Stage at diagnosis**   **pT**   **FcgRIIIA**   **FcgRIIA**    **PFS (months)**   **First-line CT**   **Response to first-line CT**   **Anti-EGFR therapy**   **Response to anti-EGFR therapy**
  ---------------------- ------------ ----------------- ----------------------------- ------------------- ------------- ------------------------ -------- -------------- -------------- ------------------ ------------------- ------------------------------- ----------------------- -----------------------------------
  IN                        Female           57                      Yes                     Colon              3                  4                3      158V/V (G/G)   131H/H (A/A)         20,0            FU+IRI+BEV                    PR                          CET                           PR
  MM                        Female           50                      No                     Rectum              3                  4                NA     158V/F (G/T)   131H/R (A/G)         12,1           CAPE+OXA+BEV                   NA                          CET                           SD
  SU                         Male            38                      No                     Rectum              2                  3                2      158V/V (G/G)   131H/R (A/G)         17,9            FU+IRI+BEV                    PR                          CET                           PR
  RAM                       Female           70                      Yes                    Rectum              2                  1                2      158V/F (G/T)   131H/H (A/A)         10,2            FU+OXA+BEV                    CR                          CET                           SD
  AA                        Female           77                      No                      Colon              3                  4                3      158V/F (G/T)   131H/H (A/A)         6,9             FU+OXA+BEV                    SD                          CET                           SD
  MC                         Male            67                      No                     Rectum              3                  4                4      158V/V (G/G)   131H/R (A/G)         6,6            CAPE+OXA+BEV                   PD                          CET                           SD
  MU                         Male            82                      NA                      Colon              2                  3                3      158V/V (G/G)   131H/R (A/G)          NP            CAPE+OXA+BEV                   SD                          No                            NA
  AN                        Female           76                      No                      Colon              2                  4                NA     158V/V (G/G)   131H/H (A/A)          NP            CAPE+OXA+BEV                   PR                          No                            NA
  VA                        Female           60                      No                      Colon              3                  4                NA     158V/F(G/T)    131H/R (A/G)         12,1           CAPE+OXA+BEV                   PR                          No                            NA
  GA                        Female           70                      No                      Colon              3                  4                4      158V/V (G/G)   131H/R (A/G)         18,2             CAPE+OXA                     PR                          CET                           SD
  SA                        Female           62                      NA                     Rectum              3                  4                3      158V/F (G/T)   131H/R (A/G)         6,4             FU+IRI+BEV                    PD                          CET                           PD
  PG                         Male            75                      No                      Colon              3                  1                2      158F/F (T/T)   131H/R (A/G)         14,8              FU+OXA                      PR                          PAN                           PR
  LRB                        Male            61                      No                      Colon              1                  3                3      158F/F (T/T)   131H/R (A/G)         7,7             FU+IRI+BEV                    SD                          CET                           SD
  VA                         Male            71                      No                      Colon              2                  4                NA     158V/V (G/G)   131H/R (A/G)         8,8            CAPE+OXA+BEV                   PD                          No                            NA
  SG                         Male            55                      No                      Colon              2                  4                NA     158V/V (G/G)   131H/H (A/A)         19,7            FU+IRI+BEV                    PD                          No                            NA
  MR                        Female           61                      No                      Colon              3                  4                NA     158V/V (G/G)   131H/R (A/G)         10,8           CAPE+OXA+BEV                   SD                          No                            NA
  MMG                       Female           43                      No                      Colon              2                  3                4      158V/V (G/G)   131H/H (A/A)         16,1            FU+OXA+BEV                    PR                          PAN                           PR
  MM                         Male            74                      No                      Colon              2                  4                3      158V/F (G/T)   131H/H (A/A)          NP             FU+IRI+BEV                    SD                          No                            NA
  GM                         Male            72                      No                     Rectum              3                  4                NA     158F/F (T/T)   131H/R (A/G)         2,6              CAPE+BEV                     SD                          PAN                           NA
  LCR                        Male            74                      No                     Rectum              3                  3                3      158V/V (G/G)   131H/R (A/G)         23,0               CAPE                       CR                          CET                           PR
  BG                        Female           47                      No                      Colon              3                  4                NA     158F/F (G/T)   131H/R (A/G)          NP            CAPE+OXA+BEV                   CR                          No                            NA
  LG                        Female           56                      No                      Colon              3                  3                3      158V/V (G/G)   131H/R (A/G)         22,4            FU+IRI+BEV                    PD                          CET                           SD
  DMV                        Male            65                      No                      Colon              2                  3                3      158V/F (G/T)   131H/R (A/G)         22,8           CAPE+OXA+BEV                   PR                          CET                           PR
  FA                        Female           66                      No                      Colon              2                  4                4      158V/F (G/T)   131H/H (A/A)         10,0            FU+IRI+BEV                    PR                          CET                           PR
  GF                         Male            56                      No                      Colon              3                  4                NA     158V/F (G/T)   131H/H (A/A)          NP             FU+IRI+BEV                    PR                          No                            NA
  MA                        Female           55                      No                     Rectum              2                  4                NA     158V/F (G/T)   131H/H (A/A)          NP            CAPE+OXA+BEV                   PR                          No                            NA
  MMR                       Female           54                      No                     Rectum              2                  1                2      158V/F (G/T)   131H/H (A/A)          NA             FU+IRI+BEV                    SD                          No                            NA
  LS                        Female           58                      No                      Colon              3                  1                NA     158V/F (G/T)   131H/R (A/G)         15,6            FU+IRI+BEV                    PR                          CET                           PR
  CD                         Male            64                      No                     Rectum              3                  4                NA     158V/F (G/T)   131H/R (A/G)         7,0             FU+IRI+BEV                    CR                          CET                           PR
  VE                        Female           56                      No                      Colon              2                  3                3      158V/F (G/T)   131H/H (A/A)         38,0            FU+IRI+BEV                    PR                          CET                           PR
  VA                         Male            81                      No                      Colon              2                  4                NA     158V/V (G/G)   131H/R (A/G)         8,9             FU+IRI+BEV                    PR                          CET                           SD
  CM                        Female           75                      No                      Colon              2                  2                3      158V/F (G/T)   131H/H (A/A)         9,8            CAPE+OXA+BEV                   SD                          PAN                           PR
  IG                         Male            73                      No                      Colon              3                  3                NA     158V/F (G/T)   131H/H (A/A)         19,5            FU+IRI+BEV                    SD                          CET                           CR
  DGS                        Male            63                      No                     Rectum              1                  4                NA     158V/V (G/G)   131H/R (A/G)         7,7              CAPE+OXA                     CR                          CET                           PD
  RO                        Female           47                      No                     Rectum              2                  3                4      158V/F (G/T)   131R/R(G/G)          9,2              CAPE+OXA                     PR                          CET                           SD
  VA                         Male            79                      No                      Colon              2                  4                NA     158V/V (G/G)   131H/R (A/G)         13,3            FU+IRI+BEV                    PR                          CET                           SD
  DFC                        Male            64                      NA                      Colon              2                  4                3      158V/F (G/T)   131H/R (A/G)         21,3             CAPE+BEV                     PR                          CET                           SD
  EI                        Female           64                      No                      Colon              2                  4                NA     158V/F (G/T)   131H/H (A/A)         16,2           CAPE+OXA+BEV                   PR                          No                            NA
  DAR                       Female           66                      Yes                     Colon              2                  4                NA     158V/F(G/T)    131H/H (A/A)          NP            CAPE+OXA+BEV                   CR                          No                            NA
  BT                         Male            56                      No                     Rectum              2                  4                NA     158V/V (G/G)   131H/R (A/G)          NP             FU+IRI+BEV                    PR                          No                            NA
  CAG                       Female           54                      No                     Rectum              2                  3                4      158V/V (G/G)   131H/H (A/A)         11,7           CAPE+IRI+BEV                   PR                          CET                           PR
  DV                        Female           78                      No                      Colon              3                  3                3      158V/F (G/T)   131H/R (A/G)         43,6            FU+IRI+BEV                    PR                          CET                           PR
  BG                         Male            65                      No                      Colon              3                  4                NA     158V/F (G/T)   131H/H (A/A)         18,3            FU+IRI+BEV                    SD                          CET                           PR
  NG                         Male            80                      No                      Colon              2                  4                NA     158F/F (T/T)   131H/H (A/A)         5,4                 FU                        PD                          No                            NA
  NR                        Female           42                      No                      Colon              3                  4                NA     158V/F(G/T)    131H/R (A/G)         6,7            CAPE+OXA+BEV                   PD                          No                            NA
  MR                         Male            60                      No                      Colon              3                  4                3      158V/F (G/T)   131H/R (A/G)         8,7             FU+IRI+BEV                    PR                          CET                           SD
  SF                        Female           62                      No                     Rectum              2                  4                NA     158V/F (G/T)   131R/R(G/G)          14,2               CAPE                       SD                          CET                           SD
  DCM                        Male            60                      No                      Colon              2                  4                NA     158V/F (G/T)   131H/R (A/G)         37,5            FU+IRI+BEV                    PR                          CET                           PR
  CML                       Female           44                      No                      Colon              3                  3                3      158V/F (G/T)   131H/R (A/G)         29,3           CAPE+OXA+BEV                   CR                          CET                           PR
  BM                         Male            66                      No                     Rectum              3                  4                NA     158V/V (G/G)   131H/R (A/G)         8,1              CAPE+BEV                     SD                          CET                           SD
  MI                        Female           40                      NA                      Colon              2                  4                NA     158V/V (G/G)   131H/R (A/G)          NP             FU+IRI+BEV                    PR                          No                            NA
  GC                        Female           57                      No                     Rectum              2                  4                NA     158V/V (G/G)   131H/H (A/A)          NP            CAPE+OXA+BEV                   PR                          No                            NA
  SC                         Male            53                      No                     Rectum              3                  4                NA     158V/V (G/G)   131H/R (A/G)          NP            CAPE+OXA+BEV                   SD                          No                            NA
  RR                         Male            77                      No                      Colon              2                  2                1      158V/F (G/T)   131H/R (A/G)         9,4             FU+OXA+BEV                    PR                          PAN                           SD
  GA                        Female           70                      No                      Colon              3                  4                4      158V/V (G/G)   131H/R (A/G)         14,6             CAPE+OXA                     PR                          No                            SD
  MP                         Male            78                      No                      Colon              3                  4                3      158V/F (G/T)   131H/R (A/G)         9,6            CAPE+OXA+CET                   SD                          CET                           SD
  CM                         Male            67                      No                     Rectum              3                  3                3      158V/V (G/G)   131H/H (A/A)         43,6              IRI+CET                     CR                          CET                           SD
  FR                        Female           55                      Yes                    Rectum              3                  4                NA     158V/V (G/G)   131R/R(G/G)          12,4             CAPE+OXA                     SD                          CET                           SD
  GL                         Male            74                      Yes                     Colon              2                  4                NA     158V/V (G/G)   131H/H (A/A)          NP             FU+OXA+BEV                    PR                          No                            NA
  TMA                       Female           66                      No                      Colon              1                  4                NA     158V/V (G/G)   131H/R (A/G)          NP             FU+IRI+BEV                    PR                          No                            NA
  CF                        Female           71                      NA                     Rectum              2                  4                NA     158V/V (G/G)   131H/R (A/G)          NP            CAPE+IRI+BEV                   PR                          No                            NA
  CE                        Female           55                      No                      Colon              1                  1                4      158V/V (G/G)   131R/R(G/G)          6,1            CAPE+IRI+CET                   SD                          CET                           SD
  SME                        Male            63                      No                      Colon              3                  4                4      158V/V (G/G)   131H/R (A/G)          NP            CAPE+IRI+CET                   PR                          CET                           PR
  GM                         Male            56                      No                     Rectum              3                  4                4      158F/F (T/T)   131H/H (A/A)         7,2            CAPE+OXA+CET                   PR                          CET                           PD
  IP                         Male            69                      No                     Rectum              3                  4                NA     158V/V (G/G)   131H/H (A/A)         7,8              CAPE+OXA                     PR                          CET                           PR
  TMR                       Female           68                      Yes                     Colon              3                  4                NA     158V/V (G/G)   131H/R (A/G)         8,8            CAPE+OXA+CET                   PD                          CET                           SD
  PM                        Female           77                      No                      Colon              1                  3                3      158F/F (T/T)   131H/H (A/A)         9,4              CAPE+OXA                     CR                          CET                           PD
  MG                         Male            64                      No                     Rectum              3                  4                NA     158V/F (G/T)   131H/H (A/A)         16,5              IRI+CET                     PD                          CET                           SD
  MG                         Male            68                      No                      Colon              3                  4                NA     158V/F (G/T)   131H/H (A/A)         2,8              CAPE+OXA                     PD                          CET                           PD
  PG                         Male            64                      No                     Rectum              3                  2                3      158V/F (G/T)   131H/H (A/A)          37                 FU                        PR                          CET                           SD
  SS                         Male            82                      No                     Rectum              3                  4                NA     158V/F (G/T)   131H/R (A/G)         19,4               CAPE                       PR                          CET                           PD
  FP                         Male            69                      Yes                     Colon              3                  4                NA     158V/F (G/T)   131H/R (A/G)         20,8              FU+IRI                      SD                          CET                           PR
  PA                        Female           70                      NA                      Colon              2                  4                3      158V/F (G/T)   131H/H (A/A)         23,3             CAPE+OXA                     CR                          No                            NA
  DLA                        Male            82                      No                      Colon              3                  3                2      158F/F (T/T)   131H/R (A/G)         28,0             CAPE+OXA                     SD                          CET                           PD

*CT*: Chemotherapy: *NA*: Not Assessable; *NP*: Not Progressed; *CR*: Complete Response; *PR*: Partial Response; *SD*: Stable Disease; *PD*: Progressive Disease; *PFS*: Progression Free Survival; *FU*: Fluorouracile; IRI: Irinotecan; *CAPE*: Capecitabine; *BEV*: Bevacizumab; PAN: Panitumumab; *CET*: Cetuximab.

Complete response (CR) was defined as complete disappearance of all detectable evidence of disease on total body computed tomography. Partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions. Stable disease (SD) was defined as everything between 30% decrease and 20% growth of tumor size. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters of target lesions. Two patients were lost at follow-up.

Analysis of FcγRIIa-H131R, FcγRIIIa-V158F polymorphisms
-------------------------------------------------------

Genomic DNA was extracted from white blood cells (WBCs) using a DNA extraction kit.(Qiagen,Valencia, CA) and stored at −20°. FcγRIIa genotyping was performed on genomic DNA by polymerase chain reaction (PCR) method adapted from a previously established protocol \[[@B17]\]. Briefly, PCR amplification was performed in 50 μl reaction mixture containing 100 ng genomic DNA, 0.4 mM of each primer, 0.4 mM dNTPs, 20 mM Tris--HCl, pH 9.0, 100 mM KCl, 0.1 mM EDTA, 1.0 mM DTT, 0.5% tween 20, and 1 U Taq DNA polymerase. The program was performed in the thermal Cycler 2770 by Applied Biosystems and consisted of an initial denaturation step at 95°C for 5′, followed by 36 cycles of 95°C for 30 seconds, 56°C for 40 seconds, 72°C for 40 seconds and a final elongation step at 72°C for 10 minutes. The primers used for PCR amplification were forward primer 5′-GGAGAAACCATCATGCTGAG-3′ and reverse primer 5'-CAATTTTGCTGCTATGGGC-3′. The resulting PCR product (289bp) was purified with the Montage SEQ~96~ Sequencing Reaction Cleanup Kits (Millipore) and prepared to sequence through a second PCR reaction using Big Dye Terminator v3.1 Cycle Sequencing Kit by Applied Biosystems in forward and reverse direction of the region of interest (96°C for 1 minutes, 25 cycle of 96°C for10 seconds, 56°C for 5 seconds and 60°C for 2 minutes). PCR product was purified with Montage SEQ~96~ Sequencing Reaction Cleanup Kits (Millipore) and direct sequencing was run with Applied Biosystems3130 Genetic Analyzers (Figure  [1](#F1){ref-type="fig"}).

![**FcγRIIa determined by direct sequencing and FcγRIIIa allotyping by allele**-**specific PCR. v Upper Panel.** FcγRIIa determined by direct sequencing: (**a**) Sequencing electropherogram obtained from a sample homozygous for allele FcγRIIa 131H/H; (**b**) Sequencing electropherogram obtained from a sample heterozygous for allele FcγRIIa 131H/R; (**c**) Sequencing electropherogram obtained from a sample homozygous for allele FcγRIIa 131R/R. **Lower Panel.** FcγRIIIa allotyping by allele-specific PCR. 100bp ladder marker, FcγRIIIa genotypes direct sequenced F/F, V/F and V/V control and CTL- negative control were represented. Examples represented respectively F/F (**a**), V/F (**b**) and V/V (**c**) patients.](1479-5876-10-232-1){#F1}

For FcγRIIIa-V158F polymorphism, allele-specific PCR method was followed. Briefly, 100 ng of genomic DNA was amplified using allele-specific common forward primer 5′-TCCAAAAGCCACACTCAAAGAC-3′ and reverse primer 5′-CTGAAGACACATTTTTACTCCCAAAC-3′. PCR amplification was performed in 25 μl reaction mixture containing 100 ng genomic DNA, 0.3 mM of each primer, 0.2 mM dNTPs, 20 mM Tris--HCl, pH 9.0, 100 mM KCl, 0.1 mM EDTA, 1.0 mM DTT, 0.5% tween 20, and 1 U Taq DNA polymerase. The program was performed in the thermal Cycler 2770 by Applied Biosystems and consisted of an initial denaturation step at 95°C for 5′, followed by 35 cycles of 94°C for 30 seconds, 64°C for 30 seconds, 72°C for 30 seconds and a final elongation step at 72°C for 10 minutes. Three DNA samples previously sequenced FcgRIIIa-V/V158, FcgRIIIa-V/F158, FcgRIIIa-F/F158 were run in all reactions (Figure  [1](#F1){ref-type="fig"}). The reaction products were run on 3% ethidium bromide-stained agarose gel. Seventy-three base pair PCR fragment either positive for valine (V) or F allele was visualized under UV light as reported previously \[[@B18]\]. To confirm FcγRIIIa genotype automatic sequencing was performed using forward primer 5′- TGT AAA ACG ACG GCC AGT TCA TCA TAA TTC TGT CTT CT-3′; reverse primer 5′--CAG GAA ACA GCT ATG ACC CTT GAG TGA TGG TGA TGT TCA-3′. The part of exon 4 which contains the polymorphic site was amplified by PCR using 100 ng genomic DNA, 0.4 mM of each primer, 0.4 mM dNTPs, 20 mM Tris--HCl, pH 9.0, 100 mM KCl , 0.1 mM EDTA, 1.0 mM DTT, 0.5% tween 20, and 1 U Taq DNA polymerase. The program was performed in the thermal Cycler 2770 by Applied Biosystems and consisted of an initial denaturation step at 95°C for 5′, followed by 36 cycles of 95°C for 30 seconds, 57°C for 30 seconds, 72°C for 30 seconds and a final elongation step at 72°C for 10 minutes. The PCR product was sequenced using the Big Dye Terminator v3.1 Cycle Sequencing Kit by Applied Biosystems.

Statistical analyses and data presentation
------------------------------------------

Associations between FcγR polymorphisms and clinical pathologic variables were evaluated by χ^2^ test. p \< 0.05 was considered statistically significant. Genotype data for FcγR polymorphisms and clinic-pathological variables were retrospectively collected and associated with response to anti-EGFR-based therapy by χ^2^ test with level of significance set at p \< 0.05. Progression-free survival (PFS) was defined as the time elapsed from the treatment initiation and tumor progression or death from any cause. The Kaplan-Meier product limit method was applied to graph PFS. Univariate analysis was done with the log-rank test. Cox proportional hazards regression was used to analyze the effect of several risk factors on PFS. Risk factors (covariates) were: age, sex, grading, response to I° line chemotherapy, FcγR polymorphisms. Ninety-five percent confidence intervals of hazard ratios were also reported. No attempts were done to analyze overall survival because of low events. Seventy-two patients were analyzed since two were lost at follow-up. Statistical analysis was performed using the MedCalc® 9.3.7.0 and Excel software.

Results
=======

Characteristics of patients and tumors
--------------------------------------

Seventy-four patients seen from May 2007 to May 2009 were studied for the FcγRIIa and FcγRIIIa polymorphisms through direct sequencing and allele specific PCR as reported in Figure  [1](#F1){ref-type="fig"}. Patients features are detailed in Table  [1](#T1){ref-type="table"}. Median age was 65 years. Genders were equally represented. Twenty-six tumors originated in the rectum 51.4% of patients had high-grade (G3) disease. The majority of lesions presented with a pT3 extent of invasion at diagnosis and 22 presented with pN+ disease. Fifty patients presented with stage IV disease, 16 with stage III and 8 with stage I/II. The majority of tumors (90.5%) did not have a mucinous component; the most represented histology was pure colonic adenocarcinoma (Table  [1](#T1){ref-type="table"}).

FcγRIIIa but not FcγRIIa polymorphisms were significantly associated with response to anti-EGFR-based therapy in kras wt tumors
-------------------------------------------------------------------------------------------------------------------------------

Fifty patients were treated with anti-EGFR-based therapy and forty nine were evaluable for clinical response (according to RECIST criteria) and PFS. Forty-five patients were treated with cetuximab, five with panitumumab. The genotypic frequencies of FcgRIIIA and FcgRIIa detected within the analyzed population were 36% VV, 54% VF ,10% FF and 36% HH, 56% HR, 8% RR, respectively. The χ^2^ test showed that there were no significant differences in the genotype frequencies (p=0.109 for V158F; p=0.183 for FcgRIIa) between patients and healthy controls. The genotypic distributions were in Hardy-Weinberg Equilibrium.

Objective responses according to FcγR polymorphisms were shown in Table  [2](#T2){ref-type="table"}. FcγRIIIa but not FcγRIIa polymorphisms were significantly associated with response to anti-EGFR-based therapy in kras wt tumors (p=0.035). The mean number of anti-EGFR therapy cycles were 15 (range: 5--27) considering panitumumab as single administration every two weeks (one administration=1 cycle) and cetuximab weekly (two administrations=1 cycle). To evaluate skin toxicity and its predictive role and correlation with FcgR polymorphisms (21), the skin related toxicity was evaluated versus the clinical response. A significant correlation was identified ( p= 0.005) between skin toxicity and clinical response (Table  [3](#T3){ref-type="table"}) while no significant correlation was identified between skin toxicity and the genotype distribution (Table  [4](#T4){ref-type="table"}).

###### 

Response to anti-EGFR therapy according to FcγR polymorphisms

                                                                                         **FcγRIIIa**   **FcγRIIa**                     
  ------------------------------------------------------------------------- ----------- -------------- ------------- --- --------- ---- ---
  **Response to anti-EGFR based chemotherapy (49 KRAS-wt evaluable pts)**                                                                 
  CR+PR                                                                      20 (40.8)        7             12        1      9      11   0
  SD                                                                         22 (44.9)        10            11        1      5      13   4
  PD                                                                         7 (14.3)         1              3        3      3      4    0
  *P*                                                                                      *0.035*                        *0.344*         

###### 

Correlation between skin toxicity and response to anti-EGFR therapy (A), and polymorphisms

                               **Response to anti-EGFR therapy**                
  --------------------------- ----------------------------------- ---- ---- --- ---------
  **Skin toxicity grade\***                                                      
  Grade 1                                      0                   3    7    5   
  Grade 2                                      0                   4    11   2   
  Grade 3                                      1                   12   4    0  *0.005*

###### 

polymorphisms

                               **V/V**   **V/F**   **F/F**  ***P\*\****    **H/H**   **H/R**   **R/R**  ***P\*\****
  --------------------------- --------- --------- --------- ------------- --------- --------- --------- -------------
  **Skin toxicity grade\***                                                                              
   Grade 1                        3         9         3                       5        10         0      
   Grade 2                        7         8         2                       5         9         3      
   Grade 3                        8         9         0     *0.2707*          7         9         1     *0.4198*

\*According to Common Toxicity Criteria for Adverse Event v3.0 and defined as any grade of rash/acne/dermatitis.

*P\*\** at Chi-Square test.

###### 

Uni- and multivariate analyses for progression-free survival (PFS)

                                                      **Events/Patients**            **Median PFS(months)**       ***P***^***1***^   **HR**^**2**^   **95% CI**^***3***^   ***P***^***4***^
  --------------------------------------------------- ------------------------------ ---------------------------- ------------------ --------------- --------------------- ------------------
  **Covariate**                                                                                                                                                             
  Age (≤70 vs \>70 years)                             32/36 vs 11/13                 17.0 vs 18.0                 0.50               0.61            0.30-1.20             0.15
  Sex (male vs female)                                24/28 vs 19/21                 18.3 vs 15.6                 0.73               1.28            0.69-2.35             0.42
  Grading (G1/G2 vs G3)                               15/20 vs 28/29                 17.3 vs 13.3                 0.007              1.83            1.01-3.31             0.04
  Response to 1^st^-line CT0 (CR vs PR vs SD vs PD)   7/8 vs 18/23 vs 12/12 vs 6/6   20.1 vs 20.0 vs 9.8 vs 7.6   0.0026             1.86            1.32-2.62             0.0004
  FcγRIIIa (VV vs VF vs FF)                           13/18 vs 25/26 vs 5/5          18.2 vs 17.3 vs 9.4          0.04               2.35            1.37-4.01             0.001
  FcγRIIa (HH vs HR vs RR)                            17/18 vs 23/27vs 3/4           16.1 vs 18.2 vs 13.3         0.61               1.19            0.72-1.96             0.49

*P*^1^ = Log Rank *P*.

HR^2^ = Cox regression HR.

CI^3^ = Confidence Intervals.

*P*^4^ = Cox's Proportional Hazards Regression *P*.

FcγR polymorphisms predict PFS in mCRC patients treated with anti-EGFR mAbs
---------------------------------------------------------------------------

The anti-EGFR treated patients were analyzed for PFS. As of June 2011, after a median follow-up for alive patients of 22.4 months, 43 patients (87.7%) had suffered tumor progression and 19 (44.2%) had died. Median PFS was 17.0 months. Analysis of prognostic factors for PFS is summarized in Table  [5](#T5){ref-type="table"}. Grading, response to 1st-line chemotherapy and FcγRIIIa polymorphisms had a significant prognostic value with univariate analysis. No prognostic ability was identified for FcγRIIa polymorphisms. The prognostic value of the grading (p=0.04, HR: 1.83, CI: 1.01-3.31), response to I°-line chemotherapy (p=0.0004,HR:1.86,CI:1.32-2.62) and FcγRIIIa (p=0.001, HR:2.35; CI:1.37-4.01) was confirmed with multivariate analysis (Table [5](#T5){ref-type="table"}). Hazard ratios of relapse and pattern of Kaplan-Meier estimated curves suggest that prognosis is particularly unfavorable for patients expressing the FcγRIIIa-158F/F genotype (median PFS V/V, V/F, F/F: 18.2 vs 17.3 vs 9.4 months) (Figure  [2](#F2){ref-type="fig"}).

![**Progression-free survival curves according to FcγR polymorphisms on 49 mCR Cpatients.** Progression-free survival was defined as time elapsed between treatment initiation and tumor progression (**a**) FcγRIIa: median PFS was 16.1 months in H/H patients (18 patients, 13 events) vs 18.2 months in H/R patients (27 patients, 23 events) vs 13.3 months in R/R patients (4 patients, 3 events); Log Rank test for three curves: p = 0.61. (**b**) FcγRIIIa: median PFS was 18.2 months in V/V patients (18 patients, 13 events) vs 17.3 months in V/F patients (26 patients, 25 events) vs 9.4 months in F/F patients (5 patients, 5 events); Log Rank test for three curves: p = 0.04.](1479-5876-10-232-2){#F2}

Discussion
==========

In this manuscript the value of the FcγRIIa-FcγRIIIa polymorphisms was retrospectively correlated to the efficacy of anti-EGFR therapy in mCRC. FcγRIIIa polymorphisms were significantly associated with response to anti-EGFR-based therapy in 49 valuable patients with kras wt tumors. The results suggested that prognosis is particularly unfavorable for patients expressing the FcγRIIIa-158F/F genotype versus patients carrying a V allele (the FcγRIIIa-158F/V or the FcγRIIIa-158V/V genotypes). On this issue, conflicting results were previously described: Bibeau et al. showed a statistically significant difference in PFS in 69 mCRC patients treated with cetuximab plus irinotecan carrying the the FcγRIIIa-158V/V genotype compared to other combinations expressing an F allele while FcγRIIa polymorphisms did not affect prognosis \[[@B15]\]. Conversely, in a series of 39 EGFR-expressing mCRC patients treated with single-agent cetuximab, Zhang et al. \[[@B14]\] found that FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms were independently associated with better PFS. However, against their hypothesis, FcγRIIIa-158V/V genotype was associated with more unfavorable clinical outcome. The authors suggest that variants of human IgG1--binding sites can influence the ADCC by modulating complex interactions with activating (FcγRIIIa) or inhibitory (FcγRIIb) receptors on effector cells.

In the present study a significant association between FcγRIIIa-158V/V genotype and response to anti-EGFR-based chemotherapy was demonstrated in 49 kras wt patients confirming that the expression of the allele F predicts a worse response and a shorter PFS. In the evaluated population, 49 patients, 5 (10.2%) carried the FF genotype for FcγRIII and 4 of 49 (8.2%) the RR genotype for FcγRII. These frequencies differ from those previously reported. In particular, Carlotti et al. investigated on 94 Italian patients affected by follicular lymphoma and thus treated with Rituximab; they reported 30 FF (32%) and 18 RR (19%) distribution \[[@B12]\]. Bibeau et al. analyzed a cohort of European subjects affected by mCRC-cetuximab treated, reporting 15 FF (22%) and 17 (28%) RR patients. Nevertheless, comparing the allelic frequencies in a population of 168 healthy donors there were no significant differences in the genotype frequencies (χ^2^ test p=0.109 for V158F; p=0.183 for FcgRIIa). Moreover we can also speculate that, although the studied population represent 74 consecutive mCRC patients coming to our observation, they all showed a good Performance Status (0--1) further validated by the neoadjuvant treatment for 23 patients (Fluopirimidine/ Irinotecan/ Bevacizumab) before hepatic metastasectomy.

The role of ADCC induced by EGFR-specific mAbs may prevent tumor outgrowth or metastasis in vivo, even in cancers insensitive to EGFR signaling inhibition \[[@B19]\]. In fact, evidences accumulated on a complex patients evaluation including the kras status but also EGF/EGFR polymorphisms and downstream pathway mutations. To date, unless a large number of patients have been treated with mAbs there are still two crucial issues: i) a small percent of kras mutated patients respond to cetuximab therapy \[[@B3],[@B4]\] and, ii) although kras wt tumors are potentially sensitive to EGFR-targeted mAbs, not all respond to anti-EGFR therapy for multiple target expression, amplification or mutations downstream \[[@B4]\]. Blockade of signal transduction may not be the only mechanism of action mediating clinical benefit of mAb-treated patients with colorectal cancer \[[@B20]\]. Cell-dependent lysis of target cells mediated by mAbs in vitro and in animal models is a crucial mechanism of action regulated by multiple factors (i.e. FcγR on Dendritic Cells, T-helper system, Tregs, B-cells, NK-cells inhibitory proteins, cytokines, etc.). Currently, we are studying the correlation between specific FCγR polymorphisms to in vitro ADCC efficacy (Trotta et al., manuscript in preparation).

Conclusions
===========

Although the exact role of FcγRIIIa-V158F polymorphism and anti-EGFR therapy require more basic studies, the presence of one allele F of the FcγRIIIa in mCRC patients predicted poor response to anti-EGFR-based therapy and worsen the prognosis.
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